Related Experiment Video
Updated: Dec 22, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
A novel cancer immunotherapy utilizing autologous tumour tissue
Haemin Park1,2, Matthew Gladstone3, Crystal Shanley2
1Department of Clinical Sciences, Colorado State University, Fort Collins, CO, USA.
Background:
With the recent interest in personalized medicine for cancer patients and immune therapy, the field of cancer vaccines has been resurrected. Previous autologous, whole cell tumour vaccine trials have not produced convincing results due, in part to poor patient selection and inactivation methos that are harsh on the cells. These methods can alter protein structure and antigenic profiles making vaccine candidates ineffective in stimulating immune response to autochthonous tumour cells.
Materials And Methods:
We investigated a novel method for inactivating tumour cells that uses UVA/UVB light and riboflavin (vitamin B2) (RF + UV). RF + UV inactivates the tumour cells' ability to replicate, yet preserves tumour cell integrity and antigenicity.
Results:
Our results demonstrate that proteins are preserved on the surface of RF + UV-inactivated tumour cells and that they are immunogenic via induction of dendritic cell maturation, increase in IFNγ production and generation of tumour cell-specific IgG. Moreover, when formulated with an adjuvant ('Innocell vaccine') and tested in different murine tumour primary and metastatic disease models, decreased tumour growth, decreased metastatic disease and prolonged survival were observed. In addition, immune cells obtained from tumour tissue following vaccination had decreased exhausted and regulatory T cells, suggesting that activation of intra-tumoural T cells may be playing a role leading to reduced tumour growth.
Conclusions:
These data suggest that the RF + UV inactivation of tumour cells may provide an efficacious method for generating autologous whole tumour cell vaccines for use in cancer patients.
Insights
A novel riboflavin (vitamin B2) plus UVA/UVB light (RF + UV) method effectively inactivates tumor cells for cancer vaccines. This preserves tumor cell antigens, enhancing immune response and reducing tumor growth in preclinical models.
Area of Science:
- Oncology
- Immunology
- Vaccine Development
Background:
- Personalized medicine and immunotherapy have renewed interest in cancer vaccines.
- Previous whole tumor cell vaccine trials faced challenges with patient selection and harsh inactivation methods that compromised antigenicity.
- Ineffective antigen presentation hinders the stimulation of immune responses against tumor cells.
Purpose of the Study:
- To investigate a novel method for inactivating tumor cells using riboflavin (vitamin B2) and UVA/UVB light (RF + UV).
- To assess if this inactivation method preserves tumor cell integrity and antigenicity for effective cancer vaccine development.
- To evaluate the efficacy of RF + UV-inactivated tumor cells as autologous whole tumor cell vaccines in preclinical cancer models.
Main Methods:
- Tumor cells were inactivated using a combination of riboflavin (vitamin B2) and UVA/UVB light (RF + UV).
- The method was assessed for its ability to preserve tumor cell surface proteins and antigenicity.
- RF + UV-inactivated tumor cells, formulated as an 'Innocell vaccine' with an adjuvant, were tested in murine tumor models.
Main Results:
- RF + UV inactivation preserved tumor cell surface proteins and antigenicity, confirmed by dendritic cell maturation and increased IFNγ production.
- Vaccination with the 'Innocell vaccine' led to reduced tumor growth, decreased metastasis, and prolonged survival in murine models.
- Analysis of immune cells from tumor tissue revealed decreased exhausted and regulatory T cells, suggesting enhanced intra-tumoral T cell activation.
Conclusions:
- The RF + UV inactivation method preserves tumor cell integrity and antigenicity.
- This novel inactivation technique shows promise for developing effective autologous whole tumor cell vaccines.
- The findings suggest RF + UV-inactivated tumor cells could be a viable strategy for cancer immunotherapy.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...